<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635033</url>
  </required_header>
  <id_info>
    <org_study_id>MS HYPE Pilot</org_study_id>
    <nct_id>NCT04635033</nct_id>
  </id_info>
  <brief_title>Intermittent Hypoxia Intervention in MS Patients</brief_title>
  <acronym>MSHYPE</acronym>
  <official_title>Safety and Tolerance of an Intermittent Intervention in MS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational cohort study investigates the safety and feasibility of an intermittent&#xD;
      hypoxia intervention in multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lake Louise Score (LLS)</measure>
    <time_frame>Change of mean LLS before vs. after 1 hour vs. after 2 hours of each session</time_frame>
    <description>Tolerance by measuring the development of acute mountain sickness during the sessions Score 3 to 5 = mild AMS Score 6 or more = severe AMS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>MS impairment measurement with a score ranging from 0.0 (normal neurological exam) to 10.0 (death due to MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25-Foot Walk (T25-FW)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Quantitative mobility and leg function performance test based on a timed 25-walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walking test (6MWT)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Maximum distance in 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole-Peg-Test (9 HPT)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Quantitative test of upper extremity function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal learning and memory test (VLMT)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Rapid and delayed recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Test for concentration and decision making</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Visuospatial Memory Test-Revised (BVMT-R)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Test for visuospatial memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frenchay Activities Index (FAI)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Measure of instrumental activities of daily living (IADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Scale Motor Cognition (FSMC)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Measure MS-related cognitive and motor fatigue in MS&#xD;
43 Mild Fatigue&#xD;
53 Medium Fatigue&#xD;
63 Severe Fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Measure severity of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Lesions</measure>
    <time_frame>Baseline, at the end of the intervention (after 3 months)</time_frame>
    <description>T2 and Gd enhancing T1 lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy</measure>
    <time_frame>Baseline, at the end of the intervention (after 3 months)</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell subsets</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>FACS analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>bpm by pulsoxymeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>During every session (2hours/session)</time_frame>
    <description>bpm by pulsoxymeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>During every session (2hours/session)</time_frame>
    <description>measured by pulsoxymeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sugar</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>mg/dl in the blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood count</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Hb, Hct, Leucocytes, Lymphocytes, Thrombocytes, Neutrophils in th blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoetin</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>GOT, GPT, GGT (blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney enzyme</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Creatinine (blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NFL</measure>
    <time_frame>Baseline, 4 weeks after starting the intervention, at the end of the intervention (after 3 months)</time_frame>
    <description>Neurofilament light chain (serum)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <description>2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MS patients with all types of MS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-60 years&#xD;
&#xD;
          -  confirmed MS (all types of MS)&#xD;
&#xD;
          -  ability to come to the outpatient clinic 2-3x/week for 3 months&#xD;
&#xD;
          -  EDSS ≤ 6.5&#xD;
&#xD;
          -  inconspicuous medical examination&#xD;
&#xD;
          -  inconspicuous ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  relapse in the last 3 months&#xD;
&#xD;
          -  EDSS progression in the last 6 months&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  contraindication for MRI&#xD;
&#xD;
          -  severe heart disease&#xD;
&#xD;
          -  severe asthma, COPD&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  severe cognitive deficits&#xD;
&#xD;
          -  chronic headache&#xD;
&#xD;
          -  renal insufficiency&#xD;
&#xD;
          -  anaemia (Hb &lt; 10 g/dl)&#xD;
&#xD;
          -  insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  severe vascular stenosis&#xD;
&#xD;
          -  former episodes of severe high mountain sickness&#xD;
&#xD;
          -  cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, INIMS</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Christoph Heesen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

